Severe suppression of Frzb/sFRP3 transcription in osteogenic sarcoma

Gene

Volumn 386, Issue 1-2, 2007, Pages 131-138

  Mandal, Deendayal ^a   Srivastava, Alok ^a   Mahlum, Eric ^a   Desai, Dinakar ^a   Maran, Avudaiappan ^a   Yaszemski, Michael ^a   Jalal, Syed M ^a   Gitelis, Steven ^b   Bertoni, Franco ^c   Damron, Tim ^d   Irwin, Ronald ^e   O'Connor, Mary ^f   Schwartz, Herbert ^g   Bolander, Mark E ^a   Sarkar, Gobinda ^a  

^a MAYO CLINIC   (United States)

^b Rush Arthr and Orthopedics Inst   (United States)

^c RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^d State University of New York Upstate Medical University: College of Medicine   (United States)

^e Beaumont Cancer Institute   (United States)

^f MAYO CLINIC   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

FRZB sFRP3; Microarray; Osteogenic sarcoma; Transcription; Tumor suppressor

Indexed keywords

MESSENGER RNA; PROTEIN; PROTEIN FRZB; PROTEIN SFRP3; RNA;

ARTICLE; BONE CELL; CANCER CELL CULTURE; CHROMOSOME 2; CONTROLLED STUDY; DOWN REGULATION; FETUS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPING; MICROARRAY ANALYSIS; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERUM; TRANSCRIPTION REGULATION; TUMOR BIOPSY; TUMOR SUPPRESSOR GENE;

BONE NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; MUSCLE PROTEINS; OSTEOSARCOMA; PROTEINS; TRANSCRIPTION, GENETIC;

EID: 33845581657     PISSN: 03781119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gene.2006.08.030     Document Type: Article

References (35)

1. DasGupta R., Kaykas A., Moon R.T., and Perrimon N. Functional genomic analysis of the Wnt-wingless signaling pathway. Science 308 (2005) 826-833
2. Fuchs B., Zhang K., Bolander M.E., and Sarkar G. Differential mRNA fingerprinting by preferential amplification of coding sequences. Gene 258 (2000) 155-163
3. Fuchs B., Zhang K., Bolander M.E., and Sarkar G. Identification of differentially expressed genes by mutually subtracted RNA fingerprinting. Anal. Biochem. 286 (2000) 91-98
4. Fuchs B., Zhang K., Schabel A., Bolander M.E., and Sarkar G. Identification of twenty-two candidate markers for human osteogenic sarcoma. Gene 2001 (2001) 245-252
5. Hoang B., Moos Jr. M., Vukicevic S., and Luyten F.P. Primary structure and tissue distribution of FRZB, a novel protein related to Drosophila frizzled, suggest a role in skeletal morphogenesis. J. Biol. Chem. 271 (1996) 26131-26137
6. Jalal S.M., and Law M.E. Utility of multicolor fluorescent in situ hybridization in clinical cytogenetics. Genet. Med. 1 (1999) 181-186
7. Jalal S.M., and Law M.E. Multicolor FISH. Methods Mol. Biol. 204 (2002) 105-120
8. Kaiser J. No meeting of minds on childhood cancer. News focus. Science 286 (1999) 1832-1834
9. Kawano Y., and Kypta R. Secreted antagonists of the Wnt signalling pathway. J. Cell Sci. 116 (2003) 2627-2634
10. Kruzelock R.P., Murphy E.C., Strong L.C., Naylor S.L., and Hansen M.F. Localization of a novel tumor suppressor locus on human chromosome 3q important in osteosarcoma tumorigenesis. Cancer Res. 57 1 (1997) 106-109
11. Larsson S.E., and Lorentzon R. The incidence of malignant bone tumors in relation to age, sex, and site: a study of osteosarcoma, chondrosarcoma, and Ewing's sarcoma diagnosed in Sweden from 1958 to 1968. J. Bone Jt. Surg. 56 (1974) 534-541
12. Lee A.Y., et al. Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene 23 (2004) 6672-6676
13. Leyns L., Bouwmeester T., Kim S.H., Piccolo S., and De Robertis E.M. Frzb-1 is a secreted antagonist of Wnt signaling expressed in the Spemann organizer. Cell 88 (1997) 747-756
14. Lonardo F., Ueda T., Huvos A.G., Healey J., and Landany M. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate. Cancer 79 (1997) 1541-1547
15. Luu H.H., et al. Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr. Cancer Drug Targets 4 (2004) 653-671
16. Masuda H., Miller C., Koeffler H.P., Battifora H., and Cline M.J. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 7716-7719
17. Miller C.W., et al. Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res. 50 (1990) 7950-7954
18. Mintz K.P., Grzesik W.J., Midura R.J., Robey P.G., Termine J.D., and Fisher L.W. Purification and fragmentation of nondenatured bone sialoprotein: evidence for a cryptic, RGD-resistant cell attachment domain. J. Bone Miner. Res. 8 (1993) 985-995
19. Moon R.T., Kohn A.D., De Ferrari G.V., and Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat. Rev., Genet. 5 (2004) 691-701
20. Nellissery M.J., et al. Evidence for a novel osteosarcoma tumor-suppressor gene in the chromosome 18 region genetically linked with Paget disease of bone. Am. J. Hum. Genet. 63 (1998) 817-824
21. Nishizuka S., Tamura G., Terashima M., and Satodate R. Loss of heterozygosity during the development and progression of differentiated adenocarcinoma of the stomach. J. Pathol. 185 (1998) 38-43
22. Nusse R., and Varmus H.E. Wnt genes. Cell 69 (1992) 1073-1087
23. Parr B.A., and McMahon A.P. Wnt genes and vertebrate development. Curr. Opin. Genet. Dev. 4 (1994) 523-528
24. Peichel C.L., Kozak C.A., Luyten F.P., and Vogt T.F. Evaluation of mouse Sfrp3/Frzb1 as a candidate for the lst, Ul, and Far mutants on chromosome 2. Mamm. Genome 9 (1998) 385-387
25. Schmitt J.F., et al. Hypermethylation of the inhibin alpha-subunit gene in prostate carcinoma. Mol. Endocrinol. 16 (2002) 213-220
26. Scholz R.B., Kabisch H., Weber B., Roser K., Dellig G., and Winkler K. Studies of the RB1 gene and the p53 gene in human osteosarcomas. Pediatr. Hematol. Oncol. 9 (1992) 125-137
27. Shiseki M., Kohno T., Nishikawa R., Sameshima Y., Mizoguchi H., and Yokota J. Frequent allelic losses on chromosomes 2q, 18q, and 22q in advanced non-small cell lung carcinoma. Cancer Res. 54 (1994) 5643-5681
28. Simon R., Burger H., Brinkschmidt C., Bocker W., Hertle L., and Terpe H.J. Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. J. Pathol. 185 (1998) 345-351
29. Simons A., et al. A novel chromosomal region of allelic loss, 4q32-q34, in human osteosarcomas revealed by representational difference analysis. Genes Chromosomes Cancer 26 (1999) 115-124
30. Suzuki H., et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet. 31 (2002) 141-149
31. Wang S., Krinks M., Lin K., Luyten F.P., and Moos Jr. M. Frzb, a secreted protein expressed in the Spemann organizer, binds and inhibits Wnt-8. Cell 88 (1997) 757-766
32. Wolf M., et al. Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. Cancer Genet. Cytogenet. 123 (2000) 128-132
33. Wunder J.S., et al. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study. J. Clin. Oncol. 23 (2005) 1483-1490
34. Yamaguchi T., et al. Allelotype analysis in osteosarcomas: frequent allele loss on 3q, 13q, 17p, and 18q. Cancer Res. 52 (1992) 2419-2423
35. Zi X., et al. Expression of Frzb/secreted frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res. 65 (2005) 9762-9770